The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Ulrich
U
Kintscher
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D063387:Cannabinoid Receptor Antagonists; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant
D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant